Jcr Pharmaceuticals Co., Ltd. (4552) Press Release
JCR Pharmaceuticals Announces Development Plan in Japan for Givinostat for Duchenne Muscular Dystrophy
Earlier from Jcr Pharmaceuticals
- Matters Concerning Controlling Shareholders (Affiliated Companies)
- JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
- JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders
- JCR Pharmaceuticals: FY2025 Third Quarter Results Briefing Session - Script（1,742KB）